Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent
type 2 diabetics as measured by the change in average daily insulin dose from baseline to
week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will
also be measured.